Skip to main content
    T

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.94
    +0.06 (+2.08%)

    Market Cap: $58.49M

    Last updated: Nov 17, 2026 at 4:28 PM ET

    Tonix Pharmaceuticals Holding Corp (TNXP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Tonix Pharmaceuticals Holding (TNXP) has a market cap of $58.49M. Its share count is up 106.67% from a year earlier. It kept -420.45% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$58.49M
    Latest price (Nov 17, 2026)$2.94

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 10.85% in the quarter ended Sep 30, 2026.

    Shares Outstanding18.44M
    Shares Change (YoY)+106.67%
    Shares Change (QoQ)+10.85%

    Valuation Ratios

    Sales and book value multiples are 1.3x and 0.3x.

    P/S Ratio1.3x
    Forward P/S1.0x
    P/B Ratio0.3x

    Valuation history and multiples

    Price Statistics

    The stock is down 81.51% over 52 weeks and trades 59.78% below its 50-day average.

    Beta (1Y)1.65
    52-Week Change-81.51%
    1-Month Change-48.69%
    3-Month Change-76.90%
    6-Month Change-78.56%
    5-Year Change-100.00%
    10-Year Change-100.00%
    Total Return (1Y)-81.51%
    Total Return (3Y CAGR)-87.53%
    Total Return (5Y CAGR)-90.20%
    Return vs SPY (1Y)-93.53%
    Max Drawdown (1Y)-85.52%
    Max Drawdown (3Y)-99.86%
    Sharpe Ratio (1Y)-2.34
    Correlation with SPY (1Y)0.31
    50-Day Average$7.31
    200-Day Average$11.65
    52-Week Range$2.81 to $20.56
    RSI (14 Days)12.7
    Average Volume (20 Days)1.07M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.57x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.57x
    Quick Ratio4.47x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -90.73% over the last 12 months, against a 5-year average of -69.94%.

    Return on Equity (ROE)-90.73%
    Return on Assets (ROA)-74.66%
    ROE (5Y Average)-69.94%
    ROA (5Y Average)-57.45%
    ROIC (5Y Average)-65.57%
    Asset Turnover0.17x
    Inventory Turnover1.00x
    Receivables Turnover3.26x
    Cash Conversion Cycle-2395 days

    Scores

    TNXP has an Altman Z-Score of -6.60, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-6.60
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $43.05M over the last 12 months is up 317.96% from the 12 months before.

    Revenue$43.05M
    Revenue Growth (YoY)+317.96%
    Gross Profit$38.45M
    Operating Income-$187.79M
    Pretax Income-$182.32M
    Net Income-$180.99M
    Reported EPS (TTM)-$12.24

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 82.29% of the $242.43M in total assets.

    Cash and Equivalents$162.79M
    Total Debt$0
    Net Cash$162.79M
    Net Cash Per Share$8.83
    Working Capital$150.11M
    Shareholder Equity$199.49M
    Book Value Per Share$10.82
    Total Assets$242.43M
    Total Liabilities$42.94M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.76M of capital spending, operating cash flow left -$170.04M of free cash flow.

    Operating Cash Flow-$165.28M
    Capital Expenditures$4.76M
    Free Cash Flow-$170.04M
    FCF Per Share-$9.91
    Depreciation and Amortization$2.31M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -436.25%.

    Gross Margin89.33%
    Operating Margin-436.25%
    Pretax Margin-423.55%
    Net Margin-420.45%
    FCF Margin-395.02%

    Dividends and Yields

    TNXP does not pay a dividend. Its free cash flow yield is -313.64%.

    FCF Yield-313.64%
    Buyback Yield-260.23%
    Shareholder Yield-260.23%

    Stock Splits

    The last split was a 1-for-100 reverse split on Feb 5, 2025.

    Last Split DateFeb 5, 2025
    Split TypeReverse split
    Split Ratio1:100

    Peer Position

    Against 6 similar companies, TNXP has the 4th highest P/S.

    P/S Ratio1.3x vs 5.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)+317.96% vs -68.62% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 193.37% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+193.37%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TNXP

    What is TNXP's market cap?

    Tonix Pharmaceuticals Holding has a market cap of $58.49M.

    How many shares of TNXP are outstanding?

    Tonix Pharmaceuticals Holding has 18.44M shares outstanding. The count is up 106.67% from a year earlier.

    Does TNXP pay a dividend?

    No. Tonix Pharmaceuticals Holding does not pay a dividend.

    How much debt does TNXP have?

    Tonix Pharmaceuticals Holding has $0 of total debt and $162.79M of cash and equivalents, a net cash position of $162.79M.